Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Mo
September 19 2023 - 4:32PM
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”)
(Nasdaq: ACRV), a clinical stage biopharmaceutical company
developing precision oncology medicines that it matches to patients
whose tumors are predicted to be sensitive to each specific
medicine by utilizing its proprietary proteomics-based patient
responder identification platform, today announced that two
abstracts have been selected for poster presentations at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics, being held from October 11-15, 2023 in Boston.
“Acrivon Predictive Precision Proteomics (AP3)
is a pioneering, next-generation precision medicine approach
engineered to overcome the limitations of traditional
genetics-based approaches, and we are excited to provide insights
into our drug-tailored ACR-368 OncoSignature patient responder
identification test that we are currently using in our ongoing
clinical trial for patient selection," said Peter Blume-Jensen,
M.D., Ph.D., chief executive officer, president, and founder of
Acrivon Therapeutics.
Abstracts Accepted for Poster
Presentation
Title: |
Validation of the OncoSignature assay, an ACR-368-tailored
response-predictive quantitative multiplexed immunofluorescent
assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368
in individual patients with cancer |
Poster
Number: |
B012 |
Presenter: |
Michail Shipitsin, vice president
of biomarker development, Acrivon Therapeutics |
Date and
Time: |
Friday, October 13 | 12:30-4:00
p.m. ET |
Title: |
Identification of biomarkers predictive of sensitivity to the
CHK1/2 inhibitor ACR-368 using high-resolution phosphoproteomics
and development of an ACR-368-tailored patient responder
identification 3-marker test, ACR-368 OncoSignature |
Poster
Number: |
C002 |
Presenter: |
Caroline Wigerup, director of
biology, Acrivon Therapeutics |
Date and
Time: |
Saturday, October 14 | 12:30-4:00
p.m. ET |
|
|
About Acrivon Therapeutics
Acrivon is a clinical stage biopharmaceutical
company developing precision oncology medicines that it matches to
patients whose tumors are predicted to be sensitive to each
specific medicine by utilizing Acrivon’s proprietary
proteomics-based patient responder identification platform, Acrivon
Predictive Precision Proteomics, or AP3. The AP3 platform enables
the creation of drug-specific proprietary OncoSignature companion
diagnostics that are used to identify the patients most likely to
benefit from Acrivon’s drug candidates. Acrivon is currently
advancing its lead candidate, ACR-368, a selective small molecule
inhibitor targeting CHK1 and CHK2 in a potentially registrational
Phase 2 trial across multiple tumor types. The company has received
fast track designation from the Food and Drug Administration, or
FDA, for the investigation of ACR-368 as monotherapy based on
OncoSignature-predicted sensitivity in patients with
platinum-resistant ovarian or endometrial cancer. Acrivon’s ACR-368
OncoSignature test, which has not yet obtained regulatory approval,
has been extensively evaluated in preclinical studies, including in
two separate, blinded, prospectively-designed studies on
pretreatment tumor biopsies collected from past third-party Phase 2
trials in patients with ovarian cancer treated with ACR-368. In
addition to ACR-368, Acrivon is also leveraging its proprietary AP3
precision medicine platform for developing its
internally-discovered preclinical stage pipeline programs,
consisting of its development candidate, ACR-2316, a selective,
dual WEE1/PKMYT1 inhibitor, and additional programs targeting these
two critical nodes in the DNA Damage Response, or DDR,
pathways.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995 about us and our
industry that involve substantial risks and uncertainties. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations or financial condition, business strategy and
plans and objectives of management for future operations, are
forward-looking statements. In some cases, you can identify
forward-looking statements because they contain words such as
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“possible,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or
expressions. Forward-looking statements are based on Acrivon’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Factors that
could cause actual results to differ include, but are not limited
to, risks and uncertainties that are described more fully in the
section titled “Risk Factors” in our reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this press release are made as of this date, and
Acrivon undertakes no duty to update such information except as
required under applicable law.
Investor and Media Contacts: Adam D. Levy,
Ph.D., M.B.A.alevy@acrivon.com
Alexandra Santos asantos@wheelhouselsa.com
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From Apr 2024 to May 2024
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From May 2023 to May 2024